MAGN — Magnera Corporation · 2026-09-07 · Verdict: WATCH · Conviction 3

Price $12.54 (screen close 2026-09-06; no live quotes available) · Mkt cap ~$449M · EV ~$2,070M · EV/LTM adj EBITDA 5.6x ($372M) · EV/LTM GAAP EBIT 32.9x ($63M) · FCF yield 20-24% on guided FY26 FCF of $90-110M · Net debt $1,621M (4.4x) · ADV $5.0M Sources read: 10-K 2025-11-25 (Items 1, 1A, 7), 10-Q 2026-08-06, 8-Ks of 2026-03-12, 2026-05-07 and 2026-08-06 (EX-99.1), DEF 14A 2026-01-14, Form 4s. No transcript was filed as an exhibit.

1. What the business actually does

Magnera makes nonwoven and specialty materials for diapers, adult incontinence, wipes, medical garments, tea bags and filtration, from 45 plants; Americas is 57% of sales and Rest of World, mostly Europe, 43%, with resin and pulp costs passed through over time (10-K 2025, Item 1). It exists only since 4 November 2024, when Berry Global's health, hygiene and specialties business merged into Glatfelter, Berry holders taking 90%.

2. Why it is mispriced — the edge case

A spin-merge plus a broken GAAP optic: Berry holders, mostly index and large-cap money, were handed 90% of a sub-$1B, 4.4x-levered stub fitting no packaging mandate. FY2025 GAAP operating income was $5M on $3,204M of sales after a $16M inventory step-up and $82M of integration charges (10-K 2025, Item 7), hence the screen's 414x EV/EBIT and 0.1% ROIC. That is stale: the Q3 release LTM column shows $63M of operating income and $372M of adjusted EBITDA (8-K 2026-08-06, EX-99.1), so the real multiples are 33x and 5.6x. Four event-driven or activist funds took the other side and now hold 28.6%, led by Madison Avenue at 7.9% and Cetus Capital VI at 7.8% (DEF 14A 2026-01-14). The qualification: at 22 months old, with the stock 17.8% below its high (screen row), forced selling is spent.

3. Unit economics and growth

Revenue is not growing. FY2025 sales rose 47% only because the merger added $1,145M; underneath, organic volume fell 2%, price fell $45M on pass-through, currency cost $32M (10-K 2025, Item 7). Nine months in, FY2026 sales of $2,445M are up 3% reported, down 5% comparable. June was the first good quarter: sales $857M, volume up 1%, adjusted EBITDA $99M against $91M on an $11M favourable price-cost spread from Project CORE and synergies. Americas adjusted EBITDA rose 16% to $71M while Rest of World fell 7% to $28M on European inflation and pass-through timing (8-K 2026-08-06, EX-99.1). Margins are thin, $372M on roughly $3.3B of sales. Pro forma adjusted EBITDA is $405M, down from $412M as the unrealised synergy add-back shrank from $48M to $35M.

4. Balance sheet and capital allocation

Debt is $1,901M against $280M of cash: net debt $1,621M, 4.4x LTM adjusted EBITDA. Disclosed are a $706M term loan at SOFR plus 4.25%, roughly 7.9%, and an undrawn $350M revolver; the other $1.2B is not detailed in the pack (10-Q 2026-08-06, Item 3). Covenants are in compliance, and management intends to refinance before maturity. Capital allocation is debt paydown, $65M in nine months, no buyback. The goodwill cushion is thin: at 29 June 2025 fair value exceeded carrying value by $134M on $1,996M in Americas and $65M on $825M in Rest of World (10-K 2025, Item 7). Alignment is weak: no open-market insider purchase in twelve months (Form 4s to 2026-03-10) and directors and officers hold 1% of the class, though PSUs vesting October 2027 pay on hurdles set off an $18.89 VWAP, 34% above today's price (DEF 14A).

5. Management: what they said versus what they did

In May the CEO promised to "deliver on our full-year 2026 Adjusted EBITDA and free cash flow guidance" (8-K 2026-05-07). In August he was "reaffirming our full-year free cash flow outlook, while holding to the lower end of our adjusted EBITDA guidance range" (8-K 2026-08-06). The 10-K guided FY2026 operating cash flow of $170-190M and free cash flow of $90-110M on $80M of capex (Item 7); the Q3 10-Q guides $150-170M on a $60M capex assumption, free cash flow unchanged. The line was held by cutting capex, not operations. Nine-month free cash flow is $32M ($76M CFO less $44M capex), so Q4 must produce $58-78M. Seasonality allows it, Q4 having supplied $96M of FY2025's $103M CFO, but it is the whole guide. FY2025 free cash flow was also presented as $126M, including a $90M "pre-Transaction" add-back on $103M CFO less $67M capex, a true $36M (10-K 2025, Item 7). Material weaknesses in internal control remain unremediated (Item 1A).

6. Valuation

Nine-month adjusted EBITDA is $282M and the implied FY2025 figure $354M, so FY2026 lands near $375M at the guided low end. The equity is a thin slice of a $2,070M enterprise value, so the thesis is deleveraging, not re-rating. Base (50%): FY2027 adjusted EBITDA $390M as the last $35M of synergies lands; two years of $100M free cash flow cut net debt to $1,421M; at today's 5.5x, equity is $724M, about $20 a share. Bear (30%): volumes return to -2% to -3%, Rest of World price-cost stays negative, FY2027 adjusted EBITDA $330M and net debt stays $1,600M; at 5.5x equity is $215M, about $6. Bull (20%): the $405M pro forma run rate is achieved and Europe recovers; 6.5x on $1,400M net debt gives $1,233M of equity, about $34. Probability weighted, roughly $18.70 against $12.54, with a left tail that takes out most of the equity. Reverse DCF: at $100M of free cash flow and a 12% cost of equity, the price implies free cash flow shrinking about 10% a year in perpetuity.

7. Catalysts and timeline

FY2026 results and first FY2027 guidance, with the 10-K in late November 2026, settle the cash flow question. Debt repayment transfers value to the equity, and a refinancing would remove or confirm the largest risk. With 28.6% activist ownership, a strategic action is possible, not forecast.

8. Risks and pre-registered kill criteria

Risks: 4.4x leverage on floating-rate debt, European softness, thin goodwill cushions, material weaknesses, no insider buying. 1. FY2026 free cash flow below $90M, or FY2027 free cash flow guided below $80M, in the FY2026 10-K. 2. Adjusted EBITDA below $85M in two consecutive quarters, against $99M in June and $90M in March. 3. Net debt not below $1,550M by the fiscal Q2 2027 10-Q, from $1,621M at 27 June 2026. 4. A goodwill impairment at either segment, or organic volume negative in two consecutive quarters.

9. Verdict and one-paragraph summary

WATCH, conviction 3. Magnera is a $3.2B revenue nonwovens business at 5.6x LTM adjusted EBITDA whose GAAP loss and 414x screen EV/EBIT hide $63M of operating income, with four activist funds holding 28.6%. The reason to wait is that the equity is only 22% of enterprise value, so the case rests on the $90-110M free cash flow guide, reaffirmed in August only after operating cash flow guidance was cut $20M and capex $20M, with $32M banked through three quarters. The FY2026 10-K answers it in about eleven weeks: a $58-78M fourth quarter with FY2027 guided at or above $90M makes this an IDEA worth roughly $20; otherwise the equity is a $6 stub.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.